Cell-based Assays - Cytotoxicity

Paving the way for safer, more effective treatments

Cell-based cytotoxicity assays have the potential to turn previously indiscriminate treatments into selective and accurate ones, sparing healthy cells. These assays grant you deep insights into your drug’s cellular impact, unveiling its strengths and weaknesses. By understanding how it interacts with life at its most fundamental level, you can pave the way for safer, more effective treatments that fulfill this vision. Each cell represents a tiny stepping stone on the path to a healthier future, and our assays ensure every step is taken with confidence and clarity.

Cell Line Selection:

  • Drug-resistant cell lines, enabling studies on specific resistance mechanisms.
  • Investigate drug interactions using our combination drug testing, uncovering potential synergies and optimizing treatment strategies.
  • Over 200 tumor cell lines available, encompassing a diverse range of cancers and genetic backgrounds.

Experimental Design:

  • 2D and 3D cell culture models available
  • Diverse readout options available, including MTT, cck8, CTG, Brdu, and more.
  • Flexible treatment times, ranging from acute exposures to chronic dosing (up to 14 days)

 

Start Your Cytotoxicity Assay
Cell-based Assays – Cytotoxicity

MODELS / SERVICES

CalcuSyn 2.0 software employed for data analysis

CI = 1: additive

CI < 1: synergism

CI > 1: antagonism

Darker signals indicative of better outcome

Committed to quality:

  • FDA part 11 compliant
  • Animal studies strictly follow AAALAC and ILAC guidelines
  • Electronically managed, traceable research data
  • Rigorous adherence to international GLP and QA best practices
  • Clients have real-time remote monitoring of studies

Want your scientific discoveries to become treatments? PharmaLegacy’s the right partner for you.

Contact Us

Providing Better Data For Critical Oncology Pipeline Decisions

To advance a compound from discovery to clinical, or to halt its development, is a huge and costly decision. For the benefit of you and your company, and for the well-being of patients in need of treatment, that decision needs to be based on correct information.

Download our Integrated In Vitro Oncology Assays brochure and see why over 300 pharmaceutical companies, including many global leaders, trust PharmaLegacy for the unbiased, accurate information they need to make critical oncology pipeline decisions.

    127

    We’re ready when you are.

    Tell us your pharmacology challenges.